Hammerstone Day Trader

While Others Wait For The News, You’ve Executed The Trade

What Is Hammerstone Day Trader?

Hammerstone Day Trader is a solution specifically for individuals who want to have the same breaking data and insight as professional Wall Street traders.

Hammerstone Day Trader Feed consists of an online data feed so you can be amongst the top 1% group of traders who are “first to know”.

Hammerstone Reports are sent 4x per day, keeping you informed and up-to-date with the markets.

Click Play Below To See How Hammerstone Day Trader Works:

All our monthly plans come with a 14-day free trial and no fixed contract.

Hammerstone Day Trader Feed

The Hammerstone Day Trader Feed is a breaking real-time news feed with context and analysis. This is similar information to what professional Wall Street traders see and is critical if you want to execute before the news filters through to mass media. With actionable ideas and running commentary, you will be amongst a small group of traders who are the first to know.

Start A 14 Day Free Trial

Hammerstone Reports

Hammerstone Reports are expertly written daily updates sent 4 times per day directly to your inbox. These reports give you an in-depth analysis of earnings reports, street recommendations, economic data, sector news, market movers and more. Here are examples of the reports:

Start A 14 Day Free Trial

Select Your Day Trader Plan

HAMMERSTONE REPORTS

4X Daily Reports

$49/mo

Start Your Free 14 Day Trial

  • Up-To-Date Reports (4x Daily)
  • News & In-Depth Analysis
  • Early Look Edition
  • Mid Morning Look Edition
  • Street Recommendations Edition
  • Daily Recap Edition
  • Delivery via Email
  • 14-Day Free Trial
  • Cancel Anytime

Start Your Free 14 Day Trial

HAMMERSTONE DAY TRADER FEED

Live Day Trader Feed

$99/mo

Start Your Free 14 Day Trial

  • Day Trader Data Feed (Curated)
  • Real-Time Breaking News With Context
  • Actionable Ideas, Running Commentary
  • Earnings Releases & Interpretation
  • Proprietary Research
  • Proprietary Index Levels
  • Delivery via Web App (No Install Required)
  • Desktop & Mobile Compatible
  • 14-Day Free Trial
  • Cancel Anytime

Start Your Free 14 Day Trial

COMPLETE DAY TRADER PACKAGE

Day Trader Data Feed + 4X Daily Reports

$129/mo

Start Your Free 14 Day Trial

  • All Features of Day Trader Data Feed & Reports
  • Day Trader Data Feed (Curated)
  • Real-Time Breaking News With Context
  • Actionable Ideas, Running Commentary
  • Earnings Releases & Interpretation
  • Proprietary Research & Index Levels
  • Delivery via Web App (No Install Required)
  • 4x Daily Editions Of Hammerstone Reports
  • Desktop & Mobile Compatible
  • 14-Day Free Trial
  • Cancel Anytime

Start Your Free 14 Day Trial

No obligations, no contracts, cancel at any time, 100% risk free.

Here's Yesterday's Day Trader Sample Feed

Please Note: This Is A Delayed Example (without the Chat Room), Not The Live Feed.

  • Posted At:2019-01-16T21:51:38Z

    CGIX @BioRunUp $CGIX three big insider buys. . 1M from a director. 100k from a director. 100k from the CEO

  • Posted At:2019-01-16T21:51:03Z

    Recode. @Recode. Pinterest is interviewing bankers a sign that the IPO is finally happening recode.net/2019/1/16/1818

  • Posted At:2019-01-16T21:44:54Z

    ISSUER: Verint Systems Inc . 1/15/19 Sale 1,432 $44.82 $64,182. . OWNERSHIP: 174,635 (Direct)

  • Posted At:2019-01-16T21:35:25Z

    ADMP up now up 13% after drug launch in US

  • Posted At:2019-01-16T21:33:27Z

    ACB down 2% after note offering

  • Posted At:2019-01-16T21:31:03Z

    PCG starting to pare some after hours gains - up just 6.7% now after the close

  • Posted At:2019-01-16T21:30:19Z

    More than 65,000 patients currently pay cash for their daily insulin each month. WESTLAKE VILLAGE, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced a direct purchase program to help those with diabetes obtain the company s inhaled insulin, Afrezza, for as little as $4 a day. Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

  • Posted At:2019-01-16T21:23:49Z

    Spirit Airlines estimated fourth quarter capacity rose 16.2%, ahead of its prior 15% guidance, due to higher-than-expected completion factor. . Estimated 4Q total revenue per available seat mile at 9.59 cents, up about 11.4% from a year ago. Expects adjusted CASM excluding fuel to rise about 5.5% year over year - SAVE

  • Posted At:2019-01-16T21:23:21Z

    PCG jumping over 11% after hours - not seeing story

  • Posted At:2019-01-16T21:22:25Z

    Some tech names little lower after close: NVDA, QCOM, AMD

  • Posted At:2019-01-16T21:21:21Z

    ADMP up 2% after drug launch in US

  • Posted At:2019-01-16T21:18:47Z

    FUL down 10% after eps

  • Posted At:2019-01-16T21:18:43Z

    $FUL -10% after its EPS and revs miss

  • Posted At:2019-01-16T21:17:38Z

    $AA down 1% after EPS

  • Posted At:2019-01-16T21:16:20Z

    Dover To Acquire BelangerExpands OPW's Access to Growing Car Wash Equipment Market. DOWNERS GROVE, Ill., Jan. 16, 2019 /PRNewswire/ -- Dover (NYSE: DOV) announced today that it has entered into an agreement to acquire the Belanger, Inc. business ("Belanger"), a leading full-line car wash equipment manufacturer. Following the close of the transaction, Belanger will become part of the OPW business unit, a global leader in fluid handling solutions, in Dover's Fluids segment.

Select Your Day Trader Plan

HAMMERSTONE REPORTS

4X Daily Reports

$49/mo

Start Your Free 14 Day Trial

HAMMERSTONE DAY TRADER FEED

Live Day Trader Feed

$99/mo

Start Your Free 14 Day Trial

COMPLETE DAY TRADER PACKAGE

Day Trader Data Feed + 4X Daily Reports

$129/mo

Start Your Free 14 Day Trial

No obligations, no contracts, cancel at any time, 100% risk free.